Systemic administration of IL-33 induces a population of circulating KLRG1hi type 2 innate lymphoid cells and inhibits type 1 innate immunity against multiple myeloma. - Guillerey C; Stannard K; Chen J; Krumeich S; Miles K; Nakamura K; Smith J; Yu Y; Ng S; Harjunpää H; Teng MW; Engwerda C; et al. (Immunology and cell biology, 2021)